SCHEMBL4240157

SCHEMBL4240157

C=CCNc1ccc(Cl)cc1C(=O)c1cccc(OC)c1OC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.46
SMN1; SMN2 Q16637 4/20 0.44
GAA P10253 3/20 0.44
KDM4E B2RXH2 4/20 0.44
ALDH1A1 P00352 3/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
LMNA P02545 2/20 0.44
NPSR1 Q6W5P4 1/20 0.44
MAPT P10636 2/20 0.41
KCNMA1 Q12791 1/20 0.41
HIF1A Q16665 1/20 0.41
HPGD P15428 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C19 P33261 1/20 0.40
TP53 P04637 1/20 0.40
KCNA3 P22001 1/20 0.40
POLB P06746 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4236612 0.90 PPARG (0.51) PPARGSMN1; SMN2GAAKDM4EALDH1A1
SCHEMBL5520431 0.78 MEN1 (0.49) SMN1; SMN2GAAKDM4EALDH1A1NPC1
SCHEMBL635552 0.76 RECQL (0.56) SMN1; SMN2GAAKDM4EALDH1A1NPC1
SCHEMBL4119074 0.76 NPC1 (0.47) SMN1; SMN2GAAKDM4EALDH1A1NPC1
SCHEMBL3586573 0.75 KDM4E (0.49) SMN1; SMN2GAAKDM4EALDH1A1NPC1
SCHEMBL11636878 0.75 MAPT (0.56) PPARGSMN1; SMN2KDM4EALDH1A1LMNA
SCHEMBL13502193 0.74 MRGPRX4 (0.46) PPARGSMN1; SMN2GAAKDM4EALDH1A1
SCHEMBL4242990 0.73 ALDH1A1 (0.39) SMN1; SMN2GAAKDM4EALDH1A1NPC1
SCHEMBL4242987 0.73 ALDH1A1 (0.39) SMN1; SMN2GAAKDM4EALDH1A1NPC1
SCHEMBL3762150 0.72 RAB9A (0.55) SMN1; SMN2GAAKDM4EALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090215743-A1 Tricyclic benzazepine derivatives and their use BAYER HEALTHCARE AG (DE) 2009-08-27 US disclosed
US-20090215743-A1 Tricyclic benzazepine derivatives and their use BAYER HEALTHCARE AG (DE) 2009-08-27 US disclosed
US-20090215743-A1 Tricyclic benzazepine derivatives and their use BAYER HEALTHCARE AG (DE) 2009-08-27 US disclosed
EP-1706413-A1 TRICYCLIC BENZAZEPINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS USED FOR THE TREATMENT OF CARDIOVASCULAR DISEASES Bayer HealthCare AG (DE) 2006-10-04 EP disclosed
WO-2005068472-A1 TRICYCLIC BENZAZEPINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS USED FOR THE TREATMENT OF CARDIOVASCULAR DISEASES BAYER HEALTHCARE AG (DE) 2005-07-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215743-A1 Tricyclic benzazepine derivatives and their use CACNA1I, HDAC3, AADAC PPARG 119/4885SMN1; SMN2 3928/4885GAA 851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.